Gansu Longshenrongfa Pharmaceutical Industry (300534) Fundamentals 2026 — P/E 90.6x, Revenue Analysis | SniperIQ
Gansu Longshenrongfa Pharmaceutical Industry (300534) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥4.0B, trading at ¥13.26 on the SHZ. This SniperIQ fundamentals page covers Gansu Longshenrongfa Pharmaceutical Industry's valuation (P/E 90.6x, P/B 5.5x), profitability (net margin 5.4%), revenue (¥878M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Gansu Longshenrongfa Pharmaceutical Industry's market cap?
Gansu Longshenrongfa Pharmaceutical Industry (300534) has a market capitalization of approximately ¥4.0B, trading at ¥13.26 on the SHZ. Market cap moves with the live share price.
What is Gansu Longshenrongfa Pharmaceutical Industry's P/E ratio?
Gansu Longshenrongfa Pharmaceutical Industry's trailing twelve-month P/E ratio is 90.6x, with a price-to-book (P/B) of 5.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Gansu Longshenrongfa Pharmaceutical Industry?
Gansu Longshenrongfa Pharmaceutical Industry runs a net profit margin of 5.4%, a gross margin of 67.8%, and an operating margin of 10.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Gansu Longshenrongfa Pharmaceutical Industry generate?
Gansu Longshenrongfa Pharmaceutical Industry reported revenue of ¥878M for fiscal year 2025, with net income of ¥44M and earnings per share (EPS) of 0.14. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Gansu Longshenrongfa Pharmaceutical Industry pay a dividend?
Gansu Longshenrongfa Pharmaceutical Industry offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Gansu Longshenrongfa Pharmaceutical Industry financially healthy?
Gansu Longshenrongfa Pharmaceutical Industry carries a debt-to-equity ratio of 0.21x and a current ratio of 1.54x, with a market beta of 0.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Gansu Longshenrongfa Pharmaceutical Industry a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Gansu Longshenrongfa Pharmaceutical Industry (300534) the key facts are: market cap ¥4.0B, P/E 90.6x, revenue ¥878M, 52-week range 6.78-14. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Gansu Longshenrongfa Pharmaceutical Industry's full fundamentals live
Get Gansu Longshenrongfa Pharmaceutical Industry's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.